__NUXT_JSONP__("/drugs/Selatinib_Ditosilate", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR\u002FErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.",fdaUniiCode:"6Q2E32HVE7",identifier:"C111764",preferredName:c,semanticType:"Pharmacologic Substance",subclassOf:["C129825","C2167"],synonyms:["SELATINIB DITOSILATE",c]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FSelatinib_Ditosilate",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Selatinib_Ditosilate","Selatinib Ditosilate","2021-10-30T13:18:21.003Z")));